SDGR Schrodinger, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1490978 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.8%
TTM net income YoY66.3%
TTM EPS YoY67.1%
Revenue 3-yr CAGR10.5%
Net income 3-yr CAGR—
Margins
Gross margin58.5%
Operating margin-49.6%
Net margin-22.0%
FCF margin-43.4%
EBITDA margin-47.5%
Returns
ROE-19.0%
ROA-9.4%
ROIC (approx.)-108.6%
Asset turnover0.43x
Leverage & solvency
Liabilities / assets50.7%
Debt / equity0.00x
Current ratio2.75x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.90x
Accruals ratio8.4%
Payout ratio—
Capex / revenue1.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $64.49M | $58.89M | $58.59M | $87.23M | $54.32M | $54.76M | $59.55M | $88.32M |
| Cost of revenue | $26.24M | $26.46M | $29.04M | $29.94M | $26.29M | $28.60M | $28.43M | $24.19M |
| Gross profit | $38.25M | $32.43M | $29.55M | $57.29M | $28.04M | $26.16M | $31.12M | $64.13M |
| R&D expense | $34.09M | $41.00M | $43.82M | $41.40M | $42.76M | $43.14M | $45.84M | $49.36M |
| SG&A expense | $20.25M | $22.71M | $22.91M | $22.71M | $21.70M | $25.19M | $25.80M | $25.78M |
| Operating income | -$26.13M | -$41.55M | -$48.79M | -$17.16M | -$45.95M | -$52.90M | -$50.89M | -$20.71M |
| Pretax income | -$37.55M | $7.35M | -$59.62M | $32.97M | -$32.63M | -$42.89M | -$59.78M | -$39.25M |
| Income tax | $156,000 | $1.37M | $408,000 | $462,000 | $162,000 | $287,000 | $28,000 | $963,000 |
| Net income | -$37.71M | $5.97M | -$60.03M | $32.51M | -$32.80M | -$43.17M | -$59.81M | -$40.22M |
| EBITDA | -$24.67M | -$40.06M | -$47.32M | -$15.72M | -$44.48M | -$51.37M | -$49.30M | -$18.95M |
| EPS (basic) | -0.50 | 0.08 | -0.81 | — | -0.45 | -0.59 | -0.82 | — |
| EPS (diluted) | -0.50 | 0.08 | -0.81 | — | -0.45 | -0.59 | -0.82 | — |
| Weighted avg. shares (diluted) | 74.87M | 75.77M | 73.99M | — | 73.61M | 73.43M | 73.06M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $246.98M | $287.85M | $260.25M | $230.52M | $181.87M | $231.98M | $337.76M | $162.66M |
| Short-term investments | $119.38M | $125.89M | $138.70M | $164.95M | $219.11M | $230.28M | $174.30M | $204.80M |
| Receivables | $48.36M | $21.39M | $27.25M | $83.04M | $29.38M | $10.07M | $20.35M | $235.69M |
| Current assets | $456.54M | $470.48M | $463.96M | $519.26M | $471.72M | $514.00M | $570.94M | $634.99M |
| PP&E, net | $19.18M | $19.46M | $20.45M | $19.46M | $20.74M | $21.71M | $22.94M | $24.20M |
| Goodwill | $4.79M | $4.79M | $4.79M | $4.79M | $4.79M | $4.79M | $4.79M | $4.79M |
| Total assets | $611.94M | $640.39M | $634.19M | $726.16M | $653.66M | $688.24M | $743.03M | $823.23M |
| Current liabilities | $166.29M | $173.84M | $169.54M | $189.14M | $145.11M | $155.77M | $165.47M | $191.75M |
| Total liabilities | $310.11M | $311.44M | $320.64M | $362.11M | $332.31M | $345.37M | $369.53M | $401.78M |
| Shareholders' equity | $301.83M | $328.96M | $313.55M | $364.05M | $321.35M | $342.87M | $373.50M | $421.44M |
| Cash flow statement | ||||||||
| Operating cash flow | -$47.58M | -$34.07M | -$14.83M | -$16.09M | -$61.87M | -$52.20M | $144.06M | -$31.11M |
| Capital expenditure | $1.29M | $362,000 | $2.51M | $41,000 | $491,000 | $314,000 | $596,000 | $873,000 |
| Free cash flow | -$48.87M | -$34.43M | -$17.34M | -$16.13M | -$62.36M | -$52.51M | $143.47M | -$31.99M |
| Investing cash flow | $5.94M | $58.62M | $44.60M | $71.41M | $11.46M | -$55.60M | $30.63M | $23.48M |
| Financing cash flow | $2.72M | $650,000 | $569,000 | $197,000 | $307,000 | $2.02M | $409,000 | $119,000 |
| Depreciation & amortization | $1.46M | $1.49M | $1.48M | $1.44M | $1.47M | $1.53M | $1.59M | $1.76M |
| Stock-based compensation | $7.93M | $8.79M | $9.07M | $9.95M | $10.85M | $10.63M | $11.57M | $12.48M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.